Abstract
We evaluated the Immuno-1 (Bayer Diagnostics, Tarrytown, New York, USA) and IMx (Abbott Laboratories, Chicago, Illinois, USA) toxoplasma IgG assays in 298 (223 fresh in-house prenatal + 75 supplied by Bayer) specimens over 15 days. Discordant results were resolved by indirect fluorescence assay (Gull Laboratories, Salt Lake City, Utah, USA). The performance of Immuno-1 assay was found to be comparable to the IMx assay. Immuno-1, being a random access analyzer with minimum hands-on time requirements may have an advantage in the overall laboratory efficiency.
Original language | English (US) |
---|---|
Pages (from-to) | 13-15 |
Number of pages | 3 |
Journal | Diagnostic Microbiology and Infectious Disease |
Volume | 27 |
Issue number | 1-2 |
DOIs | |
State | Published - Jan 1997 |
Fingerprint
ASJC Scopus subject areas
- Infectious Diseases
- Immunology and Allergy
- Virology
- Parasitology
- Microbiology
- Immunology
- Applied Microbiology and Biotechnology
Cite this
Evaluation of Immuno-1 toxoplasma IgG assay in the prenatal screening of toxoplasmosis. / Rao, Lokinendi V.; James, Olapade A.; Mann, Linda M.; Mohammad, Amin A.; Okorodudu, Anthony; Bissell, Michael G.; Petersen, John R.
In: Diagnostic Microbiology and Infectious Disease, Vol. 27, No. 1-2, 01.1997, p. 13-15.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Evaluation of Immuno-1 toxoplasma IgG assay in the prenatal screening of toxoplasmosis
AU - Rao, Lokinendi V.
AU - James, Olapade A.
AU - Mann, Linda M.
AU - Mohammad, Amin A.
AU - Okorodudu, Anthony
AU - Bissell, Michael G.
AU - Petersen, John R.
PY - 1997/1
Y1 - 1997/1
N2 - We evaluated the Immuno-1 (Bayer Diagnostics, Tarrytown, New York, USA) and IMx (Abbott Laboratories, Chicago, Illinois, USA) toxoplasma IgG assays in 298 (223 fresh in-house prenatal + 75 supplied by Bayer) specimens over 15 days. Discordant results were resolved by indirect fluorescence assay (Gull Laboratories, Salt Lake City, Utah, USA). The performance of Immuno-1 assay was found to be comparable to the IMx assay. Immuno-1, being a random access analyzer with minimum hands-on time requirements may have an advantage in the overall laboratory efficiency.
AB - We evaluated the Immuno-1 (Bayer Diagnostics, Tarrytown, New York, USA) and IMx (Abbott Laboratories, Chicago, Illinois, USA) toxoplasma IgG assays in 298 (223 fresh in-house prenatal + 75 supplied by Bayer) specimens over 15 days. Discordant results were resolved by indirect fluorescence assay (Gull Laboratories, Salt Lake City, Utah, USA). The performance of Immuno-1 assay was found to be comparable to the IMx assay. Immuno-1, being a random access analyzer with minimum hands-on time requirements may have an advantage in the overall laboratory efficiency.
UR - http://www.scopus.com/inward/record.url?scp=0030891252&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030891252&partnerID=8YFLogxK
U2 - 10.1016/S0732-8893(96)00215-5
DO - 10.1016/S0732-8893(96)00215-5
M3 - Article
C2 - 9127100
AN - SCOPUS:0030891252
VL - 27
SP - 13
EP - 15
JO - Diagnostic Microbiology and Infectious Disease
JF - Diagnostic Microbiology and Infectious Disease
SN - 0732-8893
IS - 1-2
ER -